SSA
CADL icon

Schonfeld Strategic Advisors’s Candel Therapeutics CADL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
+17,473
New +$132K ﹤0.01% 2212
2024
Q3 		– Sell
-21,452
Closed -$133K – 2069
2024
Q2 		$133K Buy
+21,452
New +$161K ﹤0.01% 1861

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schonfeld Strategic Advisors's CADL Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Candel Therapeutics (CADL) in Q2 2026: 17,473 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #2212 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CADL as recently as Q2 2024.

Schonfeld Strategic Advisors first reported a position in CADL in Q2 2024 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Schonfeld Strategic Advisors held 17,473 shares of Candel Therapeutics worth $180K as of Q2 2026.
  • Candel Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2212 holding.
  • Schonfeld Strategic Advisors first reported a position in Candel Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.